Advances in Metastatic Prostate Cancer

Dear Colleagues,

In the last two decades, unprecedented improvements in the knowledge of the biology of advanced prostate cancer have led to dramatic changes in the therapeutic landscape of this disease.

The disease state, formerly known as hormone-refractory, has now been defined as castration-resistant according to the central role which is covered by androgen-receptor machinery in all disease states. This has led to the development and use of androgen-receptor signaling inhibitors (ARSIs) which produce improved survival outcomes in metastatic-castration-resistant prostate cancer (mCRPC) patients before or after docetaxel use. In recent years, docetaxel and ARSIs have been used in earlier disease states, such as non-metastatic CRPC or metastatic-castration-sensitive prostate cancer, reducing the proposed therapeutic options in the mCRPC setting.

More recently, the use of PARP inhibitors and Lu-PSMA has exploited new therapeutic targets, enhancing the available options in mCRPC. These strategies, which improve patients’ prognosis in late phases, are being used for testing in earlier disease states. Meanwhile, molecular imaging with new radiotracers provides more accurate disease pictures. In this renewed landscape, the knowledge of genomic profiling is limited by technical challenges due to the characteristics of available tissue samples, with increasing efforts being exerted to develop reliable and reproducible liquid biopsy-based analyses.  

This Special Issue, titled “Advances in Metastatic Prostate Cancer”, aims to highlight approaches which could improve the contemporary and future management and treatment of metastatic prostate cancer.

Dr. Orazio Caffo
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.